BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FemmePharma, Inc. Creates New Holding Company And Subsidiary


10/19/2005 5:12:24 PM

WAYNE, Pa., Jan. 18 /PRNewswire/ -- FemmePharma, Inc. is pleased to announce two significant changes to its corporate structure that will enable it to effectively play an expanded role in the growing worldwide market for woman-focused pharmaceutical products.

The first major shift includes the formation of FemmePharma Holding Company, Inc. to house the FemmePharma operating companies and their expanding intellectual property estate. The second change is the creation of a new subsidiary, FemmePharma Global Healthcare, Inc., to support the company's mission of developing drugs for diseases and disorders disproportionately affecting women throughout the world.

"These changes are important because they emphasize the growing global market for treatments that specifically target women and the diseases that disproportionately affect them," explains FemmePharma, Inc. President & CEO, Gerianne Tringali DiPiano. "We are committed to developing and expanding the drugs in our pharmaceutical pipeline, quite simply, because women throughout the world need them, and these changes in our structure will allow us to smoothly transition into a company that can meet these global needs."

Ms. Tringali DiPiano explained that FemmePharma Holding Company will oversee clinical and pharmaceutical development across the company's product lines here in the U.S. and globally. She noted the company will continue to create specialty subsidiaries for its areas of therapeutic focus.

FemmePharma Global Healthcare is engaged in the ongoing development of products in the therapeutic areas of endometriosis, urinary incontinence and mastalgia in other parts of the world.

About FemmePharma, Inc.

FemmePharma was founded by Gerianne Tringali DiPiano in 1996 to target needs within the estimated $70 billion women's healthcare pharmaceutical market. FemmePharma is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman's physiology, with an eye toward the changing needs of women throughout their lives. The company has a number of drugs in development based on its proprietary technologies, including new therapeutic options for urinary incontinence and mastalgia. For more information about FemmePharma, please visit its website at http://www.femmepharmainc.com/.

FemmePharma, Inc.

CONTACT: Kim Groff, FemmePharma, Inc., +1-610-995-0801, ext. 2


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->